Demonstration of protein AA in subcutaneous fat tissue obtained by fine needle biopsy

PER WESTERMARK, BJÖRN STENKVIST, JACOB B. NATVIG, AND ELISABETH OLDING-STENKVIST

From the Departments of Pathology, Clinical Cytology, and Infectious Diseases, University Hospital, Uppsala, and Department of Clinical Immunology, the Karolinska Institute, Stockholm, Sweden, and Institute of Immunology and Rheumatology, the Rikshospital University Hospital, Oslo, Norway

SUMMARY Polarisation microscopy of material obtained by fine needle biopsy of subcutaneous tissue and stained with Congo red is a simple and reliable method for the diagnosis of systemic amyloidosis. It cannot, however, be used to differentiate histologically between different forms of amyloidosis. In the present study extracts of material obtained by fine needle biopsy of subcutaneous fat tissue from 13 patients were examined by double immunodiffusion with an antiserum against protein AA, a unique protein which forms a major part of the fibrils in secondary amyloidosis. Five of the patients showed amyloid deposits round the fat cells by conventional microscopy. In 3 of these, all with rheumatoid arthritis, protein AA was detected. Eight patients without amyloidosis and 2 with myelomatosis and amyloidosis showed no reaction with antiprotein AA antiserum. Thus the material obtained by fine needle biopsy of subcutaneous tissue could be used not only for the histological diagnosis of amyloidosis but also for a classification of systemic amyloidosis into secondary or primary based on the type of amyloid fibril protein involved.

At least 2 different classes of proteins of systemic amyloid fibrils exist. One class is derived from light chains of monoclonal immunoglobulin and is seen in primary amyloidosis and myeloma or macroglobulinaemia–Waldenström-associated amyloidosis (Glenner et al., 1971). The other class is protein AA, a previously unknown protein, which occurs mainly in secondary amyloidosis (Benditt et al., 1971). While the immunological cross-reactivity varies between the immunoglobulin-derived amyloid proteins, there is immunological identity between protein AA from different individuals by the immunoprecipitation techniques used.

In secondary amyloidosis the predisposing disease is usually evident. There are, however, cases in which the underlying disease is hidden. Since the elimination of the underlying diseases is the most important way to treat secondary amyloidosis, it is of great practical importance to know whether the amoglobin is secondary or not.

The serum protein SAA is antigenically related to protein AA and occurs in low concentration in normal serum (Benson et al., 1975b; Rosenthal and Franklin, 1975) but is present in increased concentrations in a variety of pathological conditions besides primary and secondary amyloidosis (Benson et al., 1975a; Husby et al., 1973; Husby and Natvig, 1974; Rosenthal and Franklin, 1975). Since SAA is frequently present in high concentrations in systemic amyloidosis both of primary and secondary types, the estimation of SAA concentration is of no help in distinguishing between different types of amyloidosis.

Recently, a new method utilising fine needle biopsy of subcutaneous fat tissue has been developed for the diagnosis of systemic amyloidosis (Westermark and Stenkvist, 1973, 1976). The aim of this investigation was to study the possibility of using the small tissue biopsy fragments for immunochemical detection of amyloid protein AA typical of secondary amyloidosis by using specific antiprotein AA antiserum.

Material and methods

Patients

All patients referred over a period of time to the Department of Clinical Cytology for fine needle
Demonstration of protein AA in subcutaneous fat tissue obtained by fine needle biopsy 69

biopsy of the skin owing to their being clinically suspected of suffering from amyloidosis were included in the study. One patient with known myelomatosis and amyloidosis was added to this series. Fine needle biopsy of abdominal adipose tissue was performed as described previously (Westermark and Stenkvist, 1973, 1976). For microscopic investigation aspirated tissue was spread on glass slides, air dried, stained with alkaline Congo red (Puchtler et al., 1962), and examined in polarised light. Typical green birefringence was taken as evidence for amyloid. From 7 out of the 13 patients studied, serum was drawn in order to study the occurrence of the amyloid-related serum protein SAA.

EXTRACTION OF FAT TISSUE

Material from 1 or 2 aspirations was ejected in normal saline. It was then washed twice in that solution to remove serum. After that the fragments of fat tissue were collected carefully with a small spatula and put in a small test-tube to which 0·1 ml 0·1 N NaOH was added. The tubes were kept at room temperature overnight, and thereafter the solutions were neutralised by adding 0·01 ml 1 N HCl. The resulting degraded amyloid solutions (DAM) (Pras et al., 1969) were used for double immunodiffusion analyses.

IMMUNOLOGICAL METHODS

Amyloid fibrils were isolated by the method of Pras et al. (1968) from an amyloid-laden spleen obtained from a patient with amyloidosis secondary to rheumatoid arthritis. Degraded amyloid preparation was prepared as described (Pras et al., 1969). Antiamyloid protein AA antiserum was raised in a rabbit by injections with the DAM preparation. Furthermore, an antiserum against a primary amyloid protein of \( \lambda \)IV immunoglobulin light chain origin (Cornwell III et al., 1977) was used. The antisera were absorbed with small amounts of pooled human serum. Double immunodiffusion was performed in 1% agarose gel.

Results

The results of the light microscopical investigation and of the double immunodiffusion tests in the 13 patients are seen in Table 1. Of the 13 patients 11 suffered from chronic inflammatory disease, while 2 had myelomatosis. Five had amyloid deposits as detected in the subcutaneous tissue by light microscopic investigation of preparations stained with Congo red. In all cases a typical green birefringence was seen in polarised light. The amounts of amyloid varied and were moderate in the 3 patients with rheumatoid arthritis showing it, while 1 of the patients with myelomatosis showed a heavy infiltration of amyloid between the fat cells. The diagnosis of amyloidosis was confirmed in 3 patients by rectal biopsy and in one at necropsy. No further biopsies were obtained from the fifth patient or from patients in whom the fine needle biopsies were negative for amyloidosis.

Protein AA as detected by anti-AA antiserum was found in 3 patients who all had secondary amyloidosis associated with rheumatoid arthritis (Table 1). The lines of precipitation obtained with anti-AA antiserum were clear and were identical with those of a reference DAM preparation from a case of secondary amyloidosis and of pure protein AA (Fig. 1). In contrast, no reaction with antiprotein AA was found in material obtained from the 2 patients with myeloma-associated amyloidosis or from the patients without amyloidosis (Fig. 1). No precipitation reaction was seen between material from the 5 amyloid biopsies and the anti \( \lambda \)IV amyloid antiserum.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Diagnosis</th>
<th>Amyloid in fine needle biopsy</th>
<th>Amyloid diagnosis confirmed by</th>
<th>Immunodiffusion results&lt;sup&gt;2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Extract of biopsy material</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Serum</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SAA</td>
</tr>
<tr>
<td>1</td>
<td>RA</td>
<td>–</td>
<td>NT&lt;sup&gt;3&lt;/sup&gt;</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>RA</td>
<td>++</td>
<td>NT</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>RA + osteomyelitis</td>
<td>–</td>
<td>NT</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>Osteomyelitis</td>
<td>–</td>
<td>NT</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>RA</td>
<td>+</td>
<td>NT</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>Osteomyelitis</td>
<td>–</td>
<td>NT</td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>Dermatomyelitis</td>
<td>–</td>
<td>NT</td>
<td>–</td>
</tr>
<tr>
<td>8</td>
<td>RA</td>
<td>+</td>
<td>Rectal biopsy</td>
<td>+</td>
</tr>
<tr>
<td>9</td>
<td>Tuberculosis, uraemia</td>
<td>–</td>
<td>Rectal biopsy</td>
<td>–</td>
</tr>
<tr>
<td>10</td>
<td>RA</td>
<td>+</td>
<td>Rectal biopsy</td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>RA</td>
<td>+</td>
<td>Necropsy</td>
<td>+</td>
</tr>
<tr>
<td>12</td>
<td>Myelomatosis</td>
<td>+</td>
<td>Rectal biopsy</td>
<td>–</td>
</tr>
<tr>
<td>13</td>
<td>Myelomatosis</td>
<td>+</td>
<td>Rectal biopsy</td>
<td>–</td>
</tr>
</tbody>
</table>

<sup>1</sup> The degree of amyloid infiltration graded between + and ++++. <sup>2</sup> Reaction obtained with specific antiamyloid antisera. <sup>3</sup> Not tested.
Serum was available from 5 patients without amyloidosis, and serum protein SAA was detected in all these as well as in the serum from 1 of the patients with myeloma-associated amyloidosis. In serum from 1 of the patients with rheumatoid arthritis and amyloidosis protein SAA was not detected.

Discussion

Amyloidosis can be diagnosed by means of tissue biopsy. Rectal biopsy has been the most commonly used method. In our hands the fine needle biopsy of subcutaneous fat tissue has shown a good correlation with the finding of amyloidosis in rectal biopsy. The skin biopsy has also the advantage of being simpler to perform and more convenient to the patient.

Since the amounts of tissue obtained by fine needle biopsy are small, and there were only limited amounts of amyloid substance in the subcutaneous fat tissue in 3 of the patients, the material used in the immunodiffusion experiment were extracted with a small amount of alkaline solution. With this microtechnique, however, the precipitation lines obtained with antiprotein AA antiserum were clear in all cases. Thus the new technique appears to be fairly sensitive, and a heavy infiltration of amyloid in the fat tissue is not necessary for the demonstration of protein AA by this method.

The finding of protein AA in the DAM preparations of all 3 patients with secondary amyloidosis due to rheumatoid arthritis was expected. However, protein AA is exceptionally also present in other types of systemic amyloid (Benson et al., 1975a; Husby et al., 1973), but in such cases an immunoglobulin-derived protein usually predominates. Thus, although the demonstration of protein AA is not absolutely diagnostic for secondary amyloidosis, it is highly suggestive of that type. The absence of protein AA in the fat tissue extract of the 2 patients with myelomatosis and amyloidosis is also consistent with this.

The chemical classification of amyloid substance has hitherto been undertaken almost exclusively on post-mortem materials. Recently an immunofluorescence system for the classification of amyloid proteins in situ has been developed, which is useful also for biopsies (Cornwell III et al., 1977). This seems to be the method of choice when an exact classification of an immunoglobulin-derived protein is wanted. However, the immunofluorescence technique is complicated and requires considerable experience. Therefore as an alternative method a simple immunodiffusion test of extract of subcutaneous tissue obtained by fine needle aspiration is useful, especially to answer the question whether an amyloidosis is of secondary type or not.

Supported by grants from the Research Fund of the Swedish Association against Rheumatic Diseases and the Norwegian Rheumatic Council.

References


Demonstration of protein AA in subcutaneous fat tissue obtained by fine needle biopsy


Demonstration of protein AA in subcutaneous fat tissue obtained by fine needle biopsy.

P Westermark, B Stenkvist, J B Natvig and E Olding-Stenkvist

*Ann Rheum Dis* 1979 38: 68-71
doi: 10.1136/ard.38.1.68

Updated information and services can be found at:
[http://ard.bmj.com/content/38/1/68](http://ard.bmj.com/content/38/1/68)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)